AstraZeneca's Tagrisso Approved in China Following Priority Review

AstraZeneca has been granted CFDA approval for Tagrisso, the company's third-generation EGFR inhibitor, as a treatment for non-small cell lung cancer. The oral drug was approved as a second-line treatment for EGFR T790M mutation-positive NSCLC. According to AstraZeneca, patients who are given earlier EGFR inhibitors (such as Roche's Avastin and its own Iressa) often develop the T790M mutation over time, causing resistance and providing AstraZeneca with a market for Tagrisso. The China approval was granted under CFDA priority review rules, a first for AstraZeneca in China. More details.... Stock Symbols: (NYSE: AZN) (SIX: ROG) Share this with colleagues: // //